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During the past decade, huge advantages have been made
in mapping and understanding the human-associated
intestinal microbiome and its relation with human health.
The vast amount of microorganisms that reside in our
gastrointestinal tract is being acknowledged for its role
in human physiology and due to this role, it has even
been referred to as an additional organ.[1] As a result of
the revelation of links between diseases and changes in the
intestinal bacterial composition, medical interest in the
deliberate use of bacteria or their products in treating
diseases, called bacteriotherapy, has mounted likewise.
Currently, bacteriotherapy comprises (fecal) microbial
transfer, where stools or microbial stool-derivates like
washed microbiota[2] from a donor are administered to
treat an illness in an acceptor on the one hand, and
probiotics on the other. According to the definition,
probiotics are “live microorganisms which when adminis-
tered in adequate amounts confer a health benefit on the
host.”[3] These benefits occur through interaction with
the (local) immune system, through the production of
desired metabolites and cross-feeding with present micro-
organisms but are also linked with increasing the bacterial
load. Many different bacterial and yeast strains have been
studied for their probiotic effects. Probiotics are generally
administered in doses of up to 1010 viable microorganisms
which are added to the estimated 1014 bacteria in the
human gastrointestinal tract.[4] Upon administration,
probiotics are considered to exert a transient effect,
without permanent colonization of the host after the
treatment has been ceased. In general, wash-out periods of
2 to 4 weeks are being used in clinical trials. Although the
term ’probiotics’ is highly useful to describe this type of
microorganism based therapy, it also leads to misconcep-
tions. After all, the term probiotic covers many different
microorganisms that have very different properties.
Taxonomically, probiotics cross even different domains
as both unicellular prokaryotic (bacteria) and complex cell
eukaryotic (yeast) probiotic strains are being used.
Moreover, health benefits of probiotics have been
described for different indications and their mode of
action is divers. As a result, caution is needed when
summarizing the published research results to evaluate the
efficacy of probiotics. If we want to improve the potency of
probiotic use, there is an urgent need to also recognize the
microbial view-point. Here, probiotics are approached
from a microbiologist perspective and pinpointed to
bacterial probiotics for intestinal applications. The focus
lays on the impact of specific supplementation of bacterial
strains to an existing microbial ecosystem, starting with the
probiotic strain itself.
Different probiotic strains are used and common features
of probiotics can be observed across taxonomic groups,
but the strain-specificity of a feature is often neglected.
However, apart from increasing microbial load and
thereby promoting niche competition with pathogens,
most effects of microorganisms on human health are strain
specific. This strain specificity of probiotics is well-
described for in vitro and animal models, where examples
of strain specificity are reported for probiotics belonging to
different bacterial phyla. So has strain-specific inhibiting of
acute colitis in mice been described for Bifidobacterium
longum[5] and strain-specific anti-inflammatory properties
of Lactobacillus murinus[6] in a Caco-2 cell model. Also,
for different strains of Akkermansia muciniphila, similar
anti-inflammatory effects were observed in vitro; however,
when assessing these effects in vivo in mouse models with
chronic colitis, strain-specific anti-inflammatory properties
were again observed.[7] Despite the fact that two different
A. muciniphila strains had similar probiotic features in
vitro, these features did thus not translate likewise to
mouse models with a complex microbiome background.
These examples illustrate the strain specificity of probiotic
features and also partly explain why convincing animal
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data on the effect of probiotics do not always translate
easily to the clinic. After all, these examples highlight
that the conditions created in a lab environment do not
correspond with the situation in the human intestinal
tract. When performing in vitro experiments, conditions
are created to, on the one hand enable scientific
conclusions, and on the other hand to make the bacteria
assessed thrive. Co-cultivation of different fastidious
intestinal bacterial strains in a laboratory setting is
challenging. Moreover, we still lack a lot of information
on bacteria residing in the human tract and themajority of
bacteria that are found via sequencing are currently still
unknown bacteria.[8] As a result, we cannot satisfyingly
mimic the real-life conditions when assessing the potency
of microorganisms in the laboratory. After all, in real-life
the probiotic encounters a complex microbial network
where cross-feeding, co-exclusion, and inhibition be-
tween the different bacteria all play a role in the structure
and functioning of the microbial “organ” as a whole. An
elegant and inventive way to enable in vitro assessment of
a complex human microbial community is the Simulator
of the Human Intestinal Microbial Ecosystem.[9] This
model system allows the assessment of the interaction of
probiotics with a complex human microbial community
as the in vitro assay is based on pre-inoculation with a
human intestinal sample. However, as the intestinal
microbial community is subject-specific, individual pre-
screening would be needed to assess the receptivity of a
patient’s individual microbial community as well as the
potency of a probiotic strain in that specific microbial
environment.
In mice, the resistance exerted by the indigenous complex
microbial community on the colonization potential and
impact of probiotic strains has been demonstrated.
Likewise, the degree of mucosal colonization with
probiotic strains in humans has been shown to be subject
dependent upon probiotics administration. Resistance to
colonization with probiotics could be linked to micro-
biome features as well as to local immune responses of the
hosts.[10] Besides the microbiome present, also other
underlying host factors like genetic background as well as
nutritional habits should thus be acknowledged to further
comprehend the difference in potency of a probiotic strain
in different recipients. Evidently, the nutritional habits of
the host will have an influence on the availability of specific
substrates in the intestines. Either directly or via cross-
feeding these substrates can accommodate the nutritional
needs of the probiotic to thrive and exert a desired health-
promoting effect. Behavioral changes, in general, are hard
to effectuate and this is certainly the case for dietary
preferences. Therefore, in the context of probiotic efficacy,
nutritional habits should probably be considered as
unalterably host factors. The same is true for the genetic
background of the host. Despite the fact that tools for
deliberate and specific alterations of a host-genetic
background become available, the links between host
genetics and microbiome composition can likewise be
addressed as unchangeable at this moment. Based on
cohort studies, links between the human genetic back-
ground and the composition of the microbiome are being
uncovered and by accounting for these links, studies on
probiotics will further improve. So has a decrease in
Roseburia in healthy controls significantly been associated
with genetic risk variants for inflammatory bowel
disease.[11] As Roseburia is a genus comprising well-known
butyrate-producing strains and patients with ulcerative
colitis have been shown to be depleted in butyrate-
producing Roseburia,[12] the straightforward assessment
of a butyrate-producing Roseburia strain as probiotic in
ulcerative colitis appears tempting. However, preselecting
ulcerative colitis patients without genetic risk variants for
inflammatory bowel disease that are significantly associated
with a decrease in Roseburia, will markedly facilitate
the assessment of the potency of a butyrate-producing
Roseburia strain in ulcerative colitis treatment. Indeed,
predefining patient subgroups, also based on host-genetic
features will help to improve the assessment but also the use
of probiotics, in line with personalized medicine. Instead of
generic use of probiotics for health improvement, there is a
need to evolve tomore tailoredprobiotics usewhere the host
background is matched to the metabolic needs of the
probiotic to enable an adequate therapeutic effect.
Also, for the therapeutic effect, considering the microbial
point-of-view can improve results. One of the broadly
supported indications for probiotic use is for the
prevention of antibiotic-associated diarrhea. Evidence
for this comes from a large meta-analysis where studies
with different types of antibiotics and also different types
of probiotics were summarized.[13] Antibiotic-associated
diarrhea is thought to result from destabilizing the
intestinal ecosystem by the antibiotic effect of the treatment
likewise on the intestinal microbial community. This is
substantiated by the fact that patients are also more prone
to pathogens infection and fungal overgrowth upon
antibiotic therapy. The intake of probiotics will allow
the repopulation of the intestines with a chosen microbial
strain to prevent colonization with potential pathogens.
After all, the probiotic strain will compete for intestinal
niches with potential pathogenic strains. By generalizing
both the effects of different types of antibiotics on the host
microbial community, as well as the effects of different
probiotic strains belonging to bacteria and fungi, antibiotic
treatment is thus considered as intestinal reduction of
bacteria and probiotic supplementation as a way to
increase the microbial load to enhance local immunity.
However, niche-competition of the probiotics is not
limited to pathogens and has been shown to also hinder
the recovery of the intestinal microbiome after antibiotic
intake.[14] By selectively supplementing the impaired
intestinal community with selected strains, the reconstruc-
tion of the initial microbiome after antibiotic usage can be
harmed instead of facilitated. The use of autologous fecal
transfer has been proposed as a therapeutic way out to
speed up microbiome reconstruction after antibiotic
intake; however, this is rather cumbersome and obviously
not possible if the indication for antibiotic treatment was a
bowel infection. However, by transplanting an autologous
microbial community, two important prerequisites dis-
cussed here are met. An inherently compatible “probiotic
cocktail” is given, with on the one hand host-specific
features tailored to the bacteriotherapy and on the other
hand, a functional ecosystemwith existing roles for each of
the administered bacterial constituents in the metabolic
interaction network.
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In conclusion, instead of one uniform therapy, the term
“probiotics” covers a diverse range of microorganisms
and per uniquemicroorganism inter-individual effects are
expected based on the indigenous complex microbial
ecosystem and host features. For probiotics to become a
full component of evidence-based therapy, important
changes are needed. These changes can be summarized as
a call for matching both the desired probiotic feature and
the needs of the probiotic strain to thrive in the human
host. To improve the efficacy of probiotics, underlying
host factors need thus to be acknowledged, as well as
the needs of the selected strains. By enhancing the
environmental conditions for a selected probiotic, it will
be enabled to thrive and exert its desired health-
promoting properties. By preselecting patients, the real
potency of specific strains can be evaluated in receptive
hosts. In the coming years, this combined approach will
help to identify truly health-promoting microorganisms
in targeted patient groups.
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